| Co-Investigator(Kenkyū-buntansha) |
NAKAI Kunihiko Tohoku University, School of Medicine, Associate Professor, 医学部, 助教授 (00291336)
FUKUSHIMA Shoji Kobe Gakuin University, Department of Pharmacology, Associate Professor, 薬学部, 助教授 (80248103)
HAIDA Munetaka Tokai University, School of Medicine, Professor, 医学部, 教授 (20208408)
TANABE Teruhisa Tokai University, School of Medicine, Professor, 医学部, 教授 (10119688)
KINOUE Takaaki Tokai University, School of Medicine, Assistant Professor, 医学部, 講師 (30234313)
|
|---|
| Budget Amount *help |
¥50,310,000 (Direct Cost: ¥38,700,000、Indirect Cost: ¥11,610,000)
Fiscal Year 2006: ¥10,790,000 (Direct Cost: ¥8,300,000、Indirect Cost: ¥2,490,000)
Fiscal Year 2005: ¥13,650,000 (Direct Cost: ¥10,500,000、Indirect Cost: ¥3,150,000)
Fiscal Year 2004: ¥25,870,000 (Direct Cost: ¥19,900,000、Indirect Cost: ¥5,970,000)
|
|---|
| Research Abstract |
We studied protective effects of three artificial oxygen carries of our own original development as follows;
1. Liposome-encapsulated hemoglobin (LEH),
2. Nitric-Oxide-Sulfonyl-Polyethyleneglycol-Hemoglobin (SNO-PEG-Hb)
3. Per fluorocarbon Compounds (PFC).
These artificial oxygen carriers have been tested in animal models of organ ischemia or hypoxic conditions; A. Cerebral infarction, B. Myocardial ischemia, C. Cardiac arrhythmias, D. Cancer Radiation Therapy, E. Wound Healing, F. Human Immune System, G. Skeletal Muscle Ischemia, H. Total Brain Ischemia, I. Human Platelet.
On these models, influence or difference on effects of,
α) Dose-Response relationship: 10 mL/kg, 2 mL/kg, 0.4 mL/kg, 0.08 mL/kg, 0.016 ml/kg
β) Oxygen Affinity: P50O2=45 mmHg (low) and P5002=10 mmHg (high)
γ) Individual Oxygen Carriers: LEH, SNO-PEG-Hb, PFC
δ) Prospective Utility in Blood Bank, has been explored and reported.
In summary, these artificial oxygen carriers, specifically LEH, have been proved to be protective of organ ischemia (cerebral, myocardial, skeletal muscle, arrhythmia), to facilitate wound healing, and to potentiate cancer radiation therapy at minimal effective doses of 0.08 mL/kg to 2 mL/kg depending on application and oxygen affinity, which is found to be more potent with a higher affinity (P_<50>O_2=10 mmHg). Moreover, LEH proves to be non-immunogenic to human lymphocytes, and no-interferent with human platelets, suggesting a safe, innovative, and effective clinical application once approved for human use.
|
